openPR Logo
Press release

Deadline coming up on August 9th in Lawsuit for Investors in AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

07-19-2021 09:19 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on August 9, 2021 in the lawsuit for certain investors in AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX).

A Deadline is coming up on August 9, 2021 in the lawsuit for certain investors in AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX).

A deadline is coming up on August 9, 2021 in the lawsuit filed for certain investors of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) over alleged securities laws violations by AcelRx Pharmaceuticals, Inc.

Investors who purchased shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) have certain options and there are strict and short deadlines running. Deadline: August 9, 2021. NASDAQ: ACRX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) common shares between March 17, 2020 and February 12, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 17, 2020 and February 12, 2021, the defendants made false and/or misleading statements and/or failed to disclose that: AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA, that as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays, that the foregoing conduct subjected the Company to increased regulatory scrutiny and enforcement, and that as a result, the Company's public statements were materially false and misleading at all relevant times. Those who purchased shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) have certain options and should contact the Shareholders Foundation.

Those who purchased shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline coming up on August 9th in Lawsuit for Investors in AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) here

News-ID: 2332137 • Views:

More Releases from Shareholders Foundation

Investigation announced for Long-Term Investors in shares of West Pharmaceutical Services, Inc. (NYSE: WST) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc.. Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Open Lending Corporation (NASDAQ: LPRO) over potential Wrongdoing
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation. Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings, Inc. (NYSE: BBAI)
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced. Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, Inc. (NYSE: DV)
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for AcelRx

Pain Management Therapeutics Market Future Business Opportunities 2025-2032 | Ac …
Latest Report, titled "Pain Management Therapeutics Market" Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The Pain Management Therapeutics market has been
Pain Management Therapeutics Market Future Business Opportunities 2024-2031 | Ac …
The Latest research report on the Pain Management Therapeutics Market 2024 provides a comprehensive analysis of the current market landscape, with forecasts extending to 2031. This study combines qualitative and quantitative insights to highlight significant market developments, challenges, competitive dynamics, and potential opportunities and trends shaping the Pain Management Therapeutics Market. The report covers market size, recent trends, growth projections, market share, and development status. Additionally, it examines government policies,
Pain Management Therapeutics Market See Incredible Growth 2024-2031 | AcelRx Pha …
Latest Report, titled "Pain Management Therapeutics Market" Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The Pain Management Therapeutics market has been
Investigation announced for Long-Term Investors in NASDAQ: ACRX shares) over pot …
Certain directors of AcelRx Pharmaceuticals, Inc. are under investigation concerning potential breaches of fiduciary duties. Investors who are current long term investors in AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: ACRX stocks follows a lawsuit filed against AcelRx Pharmaceuticals, Inc. over
Lawsuit filed for Investors in shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: A …
An investor, who purchased shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), filed a lawsuit over alleged violations of Federal Securities Laws by AcelRx Pharmaceuticals, Inc. Investors who purchased shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) have certain options and for certain investors are short and strict deadlines running. Deadline: August 9, 2021. NASDAQ: ACRX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Redwood City, CA based
Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era | …
The research report on Pain Management Market provides a comprehensive analysis of the market status and development trend, including types, applications, growth, opportunities, rising technology, competitive landscape and product offerings of key players. Pain Management Market report covers the present and past market scenarios, market development patterns, and is likely to proceed with a continuing development over the forecast period. Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut